Latest IPO Information

Molbio Diagnostics Ltd. IPO

IPO Date: Aug 10 to Aug 12 2026

Listing Date: Aug 17 2026

Objective

1. Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec and connected office space for our Company, Subsidiaries and Associate,
2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
3. General corporate purposes

IPO Details

Face Value ₹ 1.00 Per Share
Issue Size ₹ 626.58 - 658.39 Cr
Price Band ₹ 768.00 - ₹ 807.00 Per Share
Market LOT 18 shares
Issue Type Book building

About Company

We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapidand cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We havedeveloped our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that canoperate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.As of March 31, 2025, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious andnon-communicable diseases. As of March 31, 2025, we .... offer molecular testing for 30 diseases, includingtuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and HumanPapillomavirus (“HPV”) with 42 assays. We operate in an oligopolistic market with high entry barriers, evidencedby the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”)certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of theonly two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”)for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source:1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening,through our Subsidiary, Prognosys, Associate, OptraScan and collaboration partner - UE Lifesciences. Further, weare focussed towards building a pipeline of additional products and platforms that are currently at various stagesof development. Read More
Address

Plot No. L-46, Phase I I- D Verna Industrial Area Verna, Salcete

City

South Goa

State

Goa

Pincode

403722

Phone

0832 6724888

Email

investors@molbiodiagnostics.com

Website

www.molbiodiagnostics.com

About IPO

Listed At BSE/NSE
Lead Manager Motilal Oswal Investment Advisors Pvt Ltd
Promoters
Sriram Natarajan
Chandrasekhar Bhaskaran Nair
Shiva Sriram
Sangeetha Sriram
Sowmya Sriram
Exxora Trading LLP

Promoter's Holding

Registrar

KFIN Technologies Ltd.

Latest News

Oct
16
2026
EQUITY Posted on Oct 16th 2026

Molbio Diagnostics informs about disclosure

Molbio Diagnostics has informed that it enclosed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
13
2026
EQUITY Posted on Oct 13th 2026

Molbio Diagnostics informs about disclosure

Molbio Diagnostics has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund. 
The above information is a part of company’s filings submitted to BSE. 
Read More
Sep
24
2026
EQUITY Posted on Sep 24th 2026

Molbio Diagnostics informs about SAST

Molbio Diagnostics has informed that it enclosed disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
7
2026
EQUITY Posted on Sep 7th 2026

Molbio Diagnostics informs about press release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, Molbio Diagnostics has informed that it enclosed the Press Release on Unaudited Financial Results for the quarter ended June 30, 2026. This intimation is also available on the Company’s website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 

The above information is a part of company’s filings submitted to BSE.

Read More
Oct
23
2026
EQUITY Posted on Oct 23rd 2026

Poddar Pigments submits board meeting intimation

Poddar Pigments has informed that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of Board of Directors of the Poddar Pigments is scheduled to be held on Saturday, 31st October, 2026, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. Further, as informed by intimation letter dated 25th September, 2026, Trading Window for dealing in the securities of the Company is closed from 1st October, 2026 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 for all the designated persons of the Company and their immediate relatives.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the issue size of Molbio Diagnostics Ltd. IPO?

The issue size of Molbio Diagnostics Ltd. IPO is ₹626.58 - 658.39 crore.

The Molbio Diagnostics Ltd. IPO opens for subscription on 2026-08-10 and closes on 2026-08-12.

The price range of Molbio Diagnostics Ltd. IPO is ₹768.00 to ₹807.00.

The lot size of Molbio Diagnostics Ltd. IPO is 18 shares.

The registrar of Molbio Diagnostics Ltd. IPO is KFIN Technologies Ltd..

Molbio Diagnostics Ltd. IPO will be listed on BSE/NSE .

You will typically receive a confirmation message or notification from your broker or trading platform shortly after placing your IPO order. This confirms that your application has been submitted successfully. You can also check the order status in the IPO section of your trading account or app.

Apply early with valid UPI and PAN before 2026-08-12 to increase your chances.

The listing date of Molbio Diagnostics Ltd. IPO is 2026-08-17.

An Initial Public Offering (IPO) is when a private company sells shares to the public for the first time, enabling investors to purchase these shares and gain partial ownership in the business. For instance, if a well-known tech firm wants to grow and requires additional funds, it might choose to go public through an IPO. During this process, investors can buy shares, and the company’s stock starts trading on the stock exchange on the day of the IPO listing.

Investors can apply for an IPO through their bank or brokerage account. Many trading platforms have a specific section for IPOs where users can submit their applications online.

The primary market is where shares are offered to the public for the first time via an IPO. After the IPO, shares are traded on the secondary market (stock exchange), where existing shareholders can sell to new buyers.

Investing in an IPO offers the opportunity to become an early investor in companies with high growth potential, at a price which may be lower than their post-listing market value. It provides a chance to participate in the company's growth journey from its early stages. However, IPO investments also come with inherent risks, such as market volatility and uncertainties about the company's future performance.

The price of an IPO is established through a systematic process known as "book building." In this method, investors bid within a given price range, and the final price is set based on demand and market conditions. Several factors play a crucial role in determining the IPO price, including:

Past Financial Performance: Evaluating the company's revenue, profits, and financial stability over time

Growth Potential: Assessing future prospects based on the company's business model and market opportunities

Industry Peers: Comparing valuation metrics with similar companies in the same sector

Larger Industry Picture: Analysing overall industry trends and economic conditions that could impact the company's performance

The lock-in period for IPO shares refers to a duration during which specific investors are restricted from selling their shares post-listing. This period varies based on the type of investor:

Promoters: The lock-in period for promoters ranges from 6 months to 18 months, ensuring their commitment to the company's long-term growth

Anchor Investors: Typically, anchor investors face a shorter lock-in period of 30 to 90 days, depending on regulatory norms and the specific IPO

IPOs can be volatile and may not perform as expected in the short term. Investors risk losing capital if the stock price drops after listing, especially if the company does not meet its growth projections.

Information on upcoming IPOs is often available through brokerage platforms, financial news sites, and regulatory bodies like SEBI, which publishes details on companies going public. You can also get these details under the upcoming IPO section on Bajaj Markets.

Eligibility for an IPO typically includes:

Retail Investors: Individuals who invest in smaller amounts, usually under the “retail investor” category, with certain limits

Qualified Institutional Buyers (QIBs): Entities like mutual funds, banks, and insurance companies, who invest large sums

Non-Institutional Investors (NIIs): High-net-worth individuals or entities investing above the retail threshold

Investors must have a Demat and trading account to apply, and in some cases, certain financial or residency qualifications may apply depending on local regulations.

SME (Small and Medium Enterprise) IPOs generally carry higher risk but may provide significant growth potential. Investors should research the company’s stability, financials, and sector risks, as SME stocks can be more volatile compared to large-cap companies.

View More

Invalid Mobile Number

Invalid Full Name

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore